Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company developing small molecule medicines for diseases of cardiac and neuromuscular muscle dysfunction. The company focuses on heart failure, hypertrophic cardiomyopathy, and neuromuscular diseases, with a pipeline of muscle activators and inhibitors. It received FDA approval for its first medicine in 2025. The company has been operating for more than 25 years, beginning in South San Francisco. It became publicly traded in 2004 and pivoted to focus on muscle biology in 2008. Recent clinical trials include SEQUOIA-HCM and MAPLE-HCM, evaluating cardiac myosin inhibitors for hypertrophic cardiomyopathy treatment.